Author:
Vassilakopoulou Maria,Togun Taiwo,Dafni Urania,Cheng Huan,Bordeaux Jennifer,Neumeister Veronique M.,Bobos Mattheos,Pentheroudakis George,Skarlos Dimosthenis V.,Pectasides Dimitrios,Kotoula Vassiliki,Fountzilas George,Rimm David L.,Psyrri Amanda
Publisher
Public Library of Science (PLoS)
Reference43 articles.
1. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer;RY Tsang;Br J Cancer,2012
2. Beyond trastuzumab: new treatment options for HER2-positive breast cancer;KS Saini;Breast,2011
3. HER2-positive breast cancer: beyond trastuzumab;CG Murphy;Oncology (Williston Park),2010
4. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer;J Clin Oncol
5. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens;V Valero;J Clin Oncol,2011
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献